Regeneron Pharmaceuticals Inc. buy melinda
Summary
This prediction ended on 08.08.16 with a price of €380.06. The prediction had a final performance of 15.29%. melinda has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | 6.817% | 6.817% | 28.706% | 115.470% |
| iShares Core DAX® | 0.476% | -0.039% | 13.342% | 17.330% |
| iShares Nasdaq 100 | 1.290% | 0.504% | 40.099% | 50.534% |
| iShares Nikkei 225® | 1.300% | -2.135% | 19.861% | 4.937% |
| iShares S&P 500 | 0.829% | 0.193% | 29.756% | 43.432% |
According to melinda what are the pros and cons of Regeneron Pharmaceuticals Inc. for the foreseeable future?
Pros
Cons
Comments by melinda for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Regeneron$
Nous lançons notre couverture sur Regeneron avec une recommandation Acheter et 2017 PMV de 574 $ par action. Nous estimons Regeneron gagnera 16,75 $ par action de 6,2 milliards $ du chiffre d'affaires et de générer 2,8 milliards $ du BAIIA en 2017. En dépit du taux d'imposition plus élevé que la normale en 2016 en raison de mix géographique des bénéfices, EPS devrait croître à un TCAC de 19% par rapport à $ 12.07 en 2015 pour $ 29.35 en 2020 ...
Nous recommandons aux investisseurs achètent REGN sur la base de 35% de réduction à notre 2017 PMV de 574 $ par action. Nous croyons que l'évaluation est prise en charge par le potentiel de croissance à long terme de Regeneron des actifs clés.
Stopped prediction by melinda for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
09.11.21
09.11.22
10.11.22
Regeneron Pharmaceuticals Inc.
11.02.20
04.11.21
05.11.21
Regeneron Pharmaceuticals Inc.
02.12.18
11.01.19
11.01.19
Regeneron Pharmaceuticals Inc.
10.03.18
02.08.18
02.08.18
Regeneron Pharmaceuticals Inc.
09.09.17
26.12.17
26.12.17
Regeneron Pharmaceuticals Inc.
09.09.17
26.12.17
26.12.17
Regeneron Pharmaceuticals Inc.
01.07.13
01.01.14
01.01.14
Regeneron Pharmaceuticals Inc.
07.01.11
07.07.11
07.07.11